Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Innate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).